Literature DB >> 3614291

Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia.

P J Fialkow, J W Singer, W H Raskind, J W Adamson, R J Jacobson, I D Bernstein, L W Dow, V Najfeld, R Veith.   

Abstract

To determine whether acute nonlymphocytic leukemia develops clonally, to study the pattern of differentiation of the involved stem cells, and to determine whether clinical remissions are true remissions, we studied 27 patients with acute nonlymphocytic leukemia who were heterozygous for the X-chromosome-linked glucose-6-phosphate dehydrogenase. In each case, leukemic blast cells manifested only one type of glucose-6-phosphate dehydrogenase, indicating that the malignant process had developed from a single cell. In six elderly patients, circulating erythrocytes, platelets, or both expressed only the glucose-6-phosphate dehydrogenase found in blast cells, indicating that these leukemias had arisen from stem cells with multipotent differentiative expression. In 16 younger adults and children, erythroid cells and platelets were predominantly derived from normal stem cells. In three other cases, the stem cell that gave rise to leukemic blasts apparently also gave rise to erythroid progenitors but not to mature erythrocytes. Heterogeneity was also found during remissions. In 8 of 13 patients, restoration of nonclonal hemopoiesis and repopulation of the marrow by normal stem cells was observed during remission. In the other five patients, marrow stem cells remained partially or completely clonal, even during remission. These data indicate that acute nonlymphocytic leukemia is a heterogeneous disease with respect to differentiation of the stem cells involved by leukemia and the nature of remissions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3614291     DOI: 10.1056/NEJM198708203170802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  46 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

2.  Synergistic action of the benzene metabolite hydroquinone on myelopoietic stimulating activity of granulocyte/macrophage colony-stimulating factor in vitro.

Authors:  R D Irons; W S Stillman; D B Colagiovanni; V A Henry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1α/CCL3.

Authors:  Y Wang; A Gao; H Zhao; P Lu; H Cheng; F Dong; Y Gong; S Ma; Y Zheng; H Zhang; Y Zhang; J Xu; X Zhu; W Yuan; X Zhang; S Hao; T Cheng
Journal:  Leukemia       Date:  2016-04-25       Impact factor: 11.528

Review 4.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

5.  A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Authors:  Mao Zhang; Pariya Sukhumalchandra; Atim A Enyenihi; Lisa S St John; Sally A Hunsucker; Elizabeth A Mittendorf; Anna Sergeeva; Kathryn Ruisaard; Zein Al-Atrache; Patricia A Ropp; Haroon Jakher; Tania Rodriguez-Cruz; Gregory Lizee; Karen Clise-Dwyer; Sijie Lu; Jeffrey J Molldrem; Gary L Glish; Paul M Armistead; Gheath Alatrash
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

6.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Michael Loken; Robert B Gerbing; Phoenix A Ho; Irwin D Bernstein; Susana C Raimondi; Betsy Hirsch; Janet Franklin; Roland B Walter; Alan Gamis; Soheil Meshinchi
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

7.  FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; William G Woods; Beverly J Lange; David A Sweetser; Jerald P Radich; Irwin D Bernstein; Soheil Meshinchi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

Review 8.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

9.  Challenges in treating older patients with acute myeloid leukemia.

Authors:  Lagadinou D Eleni; Zoumbos C Nicholas; Spyridonidis Alexandros
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

Review 10.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.